Articles related to MEDICAL BREAKTHROUGHS

Learn about a ground-breaking strategy for treating uncommon brain tumors like papillary craniopharyngiomas (PCPs), where precision medicine and BRAF/MEK inhibitors marked a major improvement in brain cancer treatment by drastically reducing tumor size.

Explore how thought control has been utilized in groundbreaking technology to enable a paralyzed man to walk naturally again, unveiling a new frontier in neuroscience and potentially revolutionizing paralysis treatment.

Discover how a groundbreaking trial using a new CRISPR gene-editing technique has successfully treated a patient with T-cell leukemia, a form of the disease resistant to conventional treatments. Learn how this innovative approach could revolutionize the treatment of various diseases affecting the blood, bone marrow, and immune systems.

Pioneering studies with clemastine, an over-the-counter antihistamine, are exhibiting groundbreaking findings in the repair of myelin, a protective coating on nerve fibers damaged in multiple sclerosis, based on ReBUILD clinical trial’s MRI data.

The invention of plant-based oral insulin, which provides a more secure and efficient substitute for insulin injections, marks a significant advancement in the management of diabetes. Investigate this ground-breaking strategy that could revolutionize accessibility to diabetes treatment worldwide.

Johns Hopkins researchers develop breakthrough urine test for liver cancer, increasing early detection rates by supplementing traditional AFP testing. A groundbreaking screening test for hepatocellular carcinoma (HCC), developed by Amy Kim, a hepatologist at Johns Hopkins, and her team, has demonstrated the potential to detect liver cancer at an earlier stage than the current standard-of-care. This novel diagnostic approach seeks to identify a subset of genetic biomarkers in urine associated with HCC, thereby supplementing the traditional combination of ultrasound and alpha-fetoprotein (AFP) blood testing. AFP tests have shown variable effectiveness with detection rates ranging between 40% and 90%, and a substantial number of liver cancer patients exhibit low AFP levels or misleadingly high levels due to liver disease, reducing the reliability of AFP as a singular biomarker. The study, conducted in collaboration with the Baruch S. Blumberg Institute and published in the British Journal of Cancer in 2022, analyzed samples from over 600 patients at high risk for liver disease across five medical centers. Kim’s team demonstrated that the combined use of urine circulating tumor DNA (ctDNA) testing and AFP increased detection sensitivity from 40% to 77% in early-stage liver cancer, and from 62% to 92% in the very early […]